Lexeo Therapeutics Inc. C... (LXEO)
NASDAQ: LXEO
· Real-Time Price · USD
6.62
-0.08 (-1.19%)
At close: Oct 03, 2025, 3:59 PM
6.49
-1.96%
After-hours: Oct 03, 2025, 07:14 PM EDT
Lexeo Therapeutics Common Stock Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | 1.94M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 531K | 37K | 85.55K |
Cost of Revenue | 510K | 501K | n/a | 509K | 496K | 476K | 490K | 460K | 446.06K | 446.94K | n/a | n/a | 351.3K | 6.7K |
Gross Profit | -510K | -501K | 972K | -509K | -496K | -476K | -490K | -460K | -446.06K | -446.94K | n/a | 531K | -314.3K | 78.85K |
Operating Income | -30.69M | -33.8M | -27.38M | -31.54M | -23.55M | -23.29M | -14.97M | -20.27M | -13.97M | -19.29M | -15.2M | -17.48M | -15.31M | -12.52M |
Interest Income | 1.27M | 1.19M | 1.49M | 2.09M | 2.35M | 1.65M | 1.1M | 488K | 590K | 687K | 676K | 456K | 177K | 17.28K |
Pretax Income | -26.1M | -32.66M | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M | -20.11M | -13.44M | -18.66M | -14.58M | -17.05M | -15.14M | -12.5M |
Net Income | -26.1M | -32.66M | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M | -20.11M | -13.44M | -18.66M | -14.58M | -17.05M | -15.14M | -12.5M |
Selling & General & Admin | 15.97M | 16.63M | 9.02M | 8.12M | 6.99M | 7.55M | 6.76M | 3.03M | 2.74M | 2.85M | 3.81M | 2.65M | 3.08M | 2.45M |
Research & Development | 14.72M | 17.17M | 18.37M | 23.42M | 16.56M | 15.74M | 8.21M | 17.25M | 11.24M | 16.44M | 11.39M | 15.36M | 12.27M | 10.15M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 6K | n/a | -3K | -4K | n/a | n/a | n/a | n/a |
Operating Expenses | 30.69M | 33.8M | 27.38M | 31.54M | 23.55M | 23.29M | 14.97M | 20.27M | 13.97M | 19.29M | 15.2M | 18.01M | 15.35M | 12.6M |
Interest Expense | 59K | 28K | 30K | 35K | 35K | 37K | 50K | 52K | 53K | 50K | 54K | 29K | 9K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 30.69M | 33.8M | 27.38M | 31.54M | 23.55M | 23.29M | 14.97M | 20.27M | 13.97M | 19.29M | 15.2M | 18.01M | 15.35M | 12.6M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2 |
Shares Outstanding (Basic) | 43.57M | 33.11M | 33.08M | 33.06M | 33M | 27.98M | 27.31M | 25.17M | 25.17M | 25.17M | 25.17M | 25.17M | 25.17M | 26.65M |
Shares Outstanding (Diluted) | 43.57M | 33.11M | 33.08M | 33.06M | 33M | 27.98M | 27.31M | 25.17M | 25.17M | 25.17M | 25.17M | 25.17M | 25.17M | 26.65M |
EPS (Basic) | -0.6 | -0.99 | -0.78 | -0.89 | -0.64 | -0.77 | -0.52 | -0.8 | -0.53 | -0.74 | -0.58 | -0.68 | -0.6 | -0.47 |
EPS (Diluted) | -0.6 | -0.99 | -0.78 | -0.89 | -0.64 | -0.77 | -0.52 | -0.8 | -0.53 | -0.74 | -0.58 | -0.68 | -0.6 | -0.47 |
EBITDA | -25.53M | -32.12M | -25.4M | -28.95M | -23.05M | -21.17M | -13.65M | -19.6M | -13.53M | -18.84M | -14.08M | -16.68M | -15.13M | -12.51M |
EBIT | -26.04M | -32.62M | -25.92M | -29.45M | -21.2M | -21.64M | -14.14M | -20.06M | -13.39M | -18.61M | -14.52M | -17.03M | -15.13M | -12.52M |
Depreciation & Amortization | 510K | 501K | 521K | 509K | 496K | 476K | 490K | 460K | 446K | 447K | 445K | 342K | n/a | 6.7K |